Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the…
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 14, 2025 10:48 ET | Source: Celldex Therapeutics, Inc. 77% of…